Novo Nordisk A/S: Genetic Diseases, Inborn trials

The registry lists 22 Genetic Diseases, Inborn studies with Novo Nordisk A/S as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 2Phase 3 8Phase 4 3No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2CompletedNCT03847909Phase 2Results posted
• Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan SyndromeCompletedNCT01927861Phase 3Results posted
• Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or ParentsCompletedNCT01245374Phase 4Results posted
• A Study of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseCompletedNCT04987489Phase 2
• A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)Active, not recruitingNCT04624659Phase 3
• Long Term Extension Study in Patients With Primary HyperoxaluriaActive, not recruitingNCT04042402Phase 3
• Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)CompletedNCT03435627
• Growth Response in Girls With Turner SyndromeCompletedNCT01734486Phase 4
• Induction of Puberty With 17-beta Estradiol in Girls With Turner SyndromeCompletedNCT01710696Phase 3
• Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner SyndromeCompletedNCT01604161
• Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone DeficiencyCompletedNCT01563926Phase 3
• Safety and Efficacy of Long-term Somatropin Treatment in ChildrenCompletedNCT01543867
• Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658CompletedNCT01529944Phase 3
• Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan SyndromeCompletedNCT01529840Phase 3
• Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner SyndromeCompletedNCT01518062Phase 4
• Use of Somatropin in Turner SyndromeCompletedNCT01518036Phase 3
• Special Survey for Long Term ApplicationCompletedNCT01516229
• A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With SomatropinCompletedNCT01435629
• Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult VolunteersCompletedNCT01401244Phase 1
• Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth HormoneCompletedNCT01327924
• Observational Prospective Study on Patients Treated With Norditropin®CompletedNCT00960128
• Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi SyndromeCompletedNCT00705172